イシガキ　ケイコ   ISHIGAKI Keiko   石垣　景子    所属   医学部 医学科（東京女子医科大学病院）    職種   准教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Continuous adipose-derived stem cell therapy from the neonatal stage effectively reduces Duchenne muscular dystrophy symptoms in rats.
掲載誌名	正式名：Stem cell research & therapy 略　 称：Stem Cell Res Ther ISSNコード：17576512/17576512
掲載区分	国外
巻・号・頁	16(1),pp.452
著者・共著者	Yuki Kihara, Masanari Ikeda, Ryo Takagi, Keiko Ishigaki, Keitaro Yamanouchi, Satoru Nagata, Masayuki Yamato
発行年月	2025/08
概要	BACKGROUND:The optimal timing for mesenchymal stem cell (MSC) therapy in Duchenne muscular dystrophy (DMD) remains unclear.METHODS:Neonatal DMD rats received intraperitoneal adipose-derived MSCs according to three schedules: early (postnatal days 1 and 14), continuous (days 1, 14, 28, and 42), or late (days 28 and 42). Wild-type rats and untreated DMD rats served as controls. Functional and histological outcomes were assessed on day 56.RESULTS:Continuous administration significantly attenuated the decline in grip strength across ten consecutive measurements (- 11% vs. -37% in DMD controls), and also reduced serum creatine kinase levels and diaphragmatic fibrosis (p < 0.05). Early or late treatment alone showed limited benefit. GFP-labelled cells were rarely detected in muscle, indicating minimal engraftment and suggesting paracrine-mediated effects. Molecular profiling showed lower CDKN2A together with higher CDKN1A, IL-10, VEGF-A and IGF-1 in the continuous group, revealing an anti-senescence, pro-regenerative profile that paralleled the functional gains.CONCLUSION:Early and sustained MSC administration offers superior structural and functional protection in DMD rats, highlighting the importance of treatment timing in maximizing therapeutic efficacy.
DOI	10.1186/s13287-025-04594-x
PMID	40859366